EUVIMEDEUVIMED entdecken
Zurückgezogene PublikationOpen Access · CC BY 4.0

RETRACTED: SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway

Tianyu Wu, Xing Ji, Yongyang Yun, Xiaofei Wang, Ying Gan, Yu Fan, Qian Zhang iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0333202 ↗

Kurz gefasst

Zurückgezogene Publikation in der Zeitschrift PLOS One, 2025. Verfasst von Tianyu Wu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, DNA Methylation, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Renal cell carcinoma (RCC) ranks among the most prevalent malignancies of the genitourinary system, with a steadily rising incidence. Despite growing attention, the etiology and underlying mechanisms of RCC remain incompletely understood. Epigenetic modifications, particularly DNA methylation, have emerged as critical regulators in various malignancies, including RCC. Sperm-associated antigen 6 (SPAG6), initially identified in human testicular tissue and considered a marker for testicular tumors, has been associated with the pathophysiology of several malignancies. This study aimed to elucidate the role of aberrant SPAG6 methylation in RCC progression.

Methods

We first analyzed SPAG6 expression and methylation patterns in RCC and adjacent normal tissues using data from The Cancer Genome Atlas (TCGA) and the Epigenome-Wide Association Study (EWAS) databases. Clinical tissue specimens from Peking University First Hospital were then examined to explore the association between SPAG6 expression/methylation and the clinicopathological features of RCC patients. The correlation between SPAG6 expression and promoter methylation was further validated in RCC cell lines. Functional roles of SPAG6 in cell proliferation, invasion, cell cycle regulation, and apoptosis were investigated through in vitro cellular assays and in vivo xenograft models. Finally, transcriptome sequencing was performed to explore the molecular mechanisms by which SPAG6 affects RCC development.

Results

SPAG6 expression was markedly downregulated in RCC tissues compared to adjacent non-tumorous counterparts, because of promoter CpG hypermethylation. SPAG6 expression was associated with tumor stage in RCC patients. Functional assays demonstrated that SPAG6 suppresses RCC cell proliferation, invasion, and cell cycle progression, while promoting apoptosis. Mechanistically, SPAG6 inhibited RCC progression by negatively regulating the PI3K/AKT/mTOR signaling pathway.

Conclusions

SPAG6 functions as a tumor suppressor in RCC, with its silencing driven by promoter hypermethylation. Through modulation of the PI3K/AKT/mTOR pathway, SPAG6 plays a vital role in restraining RCC initiation and progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellDNA MethylationKidney NeoplasmsHumansTOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCell Line, TumorSignal TransductionAnimalsMaleDisease ProgressionCell ProliferationMiceGene Expression Regulation, NeoplasticFemaleMiddle AgedApoptosisMice, NudePromoter Regions, Genetic

Substanzen

TOR Serine-Threonine KinasesProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMTOR protein, human

Autor:innen und Institutionen

  • Department of Urology, Peking University First Hospital, Beijing, China.
  • Institution of Urology, Peking University, Beijing, China.
  • Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, China.
  • National Urological Cancer Center, Beijing, China.
  • Department of General Surgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
  • Department of Urology, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Qian Zhang

Zitieren

APA

Wu, T., Ji, X., Yun, Y., Wang, X., Gan, Y., Fan, Y., & Zhang, Q. (2025). RETRACTED: SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway. PLOS One. https://doi.org/10.1371/journal.pone.0333202

Vancouver

Wu T, Ji X, Yun Y, Wang X, Gan Y, Fan Y, et al. RETRACTED: SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway. PLOS One. 2025. doi:10.1371/journal.pone.0333202

BibTeX
@article{Wu2025,
  author = {Wu, Tianyu and Ji, Xing and Yun, Yongyang and Wang, Xiaofei and Gan, Ying and Fan, Yu and Zhang, Qian},
  title = {RETRACTED: SPAG6 hypermethylation silences a novel tumor suppressor and inhibits renal cell carcinoma progression via PI3K/AKT/mTOR pathway},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0333202}
}
Kostenlos starten →